PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24986000-13 2014 Noteworthy, the American guidelines introduce also ACE inhibitors - fosinopril and quinapril, on the other hand beta-blockers don t involve nebivolol. Quinapril 83-92 angiotensin I converting enzyme Homo sapiens 51-54 25680080-5 2015 ACE inhibitors such as ramipril, captopril, perindopril, quinapril, lisinopril, enalapril, and trandolapril have been documented to ameliorate the above neurodegenerative disorders. Quinapril 57-66 angiotensin I converting enzyme Homo sapiens 0-3 21496825-1 2011 The separation of structurally related angiotensin-converting enzyme (ACE) inhibitors lisinopril, cilazapril, ramipril and quinapril and their corresponding active diacid forms (prilates) by conventional TLC silica gel 60 plates was contrasted with that afforded by monolithic ultra-thin-layer chromatographic (UTLC) plates. Quinapril 123-132 angiotensin I converting enzyme Homo sapiens 70-73 24285767-8 2013 ACE inhibitors evaluated in the studies were captopril, lisinopril, perindopril, quinapril, and ramipril. Quinapril 81-90 angiotensin I converting enzyme Homo sapiens 0-3 24250503-7 2012 Very good correlation (r = 0.91; water-ethanol solvent system) between the chromatographically obtained hydrophobicity parameters and calculated log p values confirmed the selection of ACE inhibitors since lisinopril and quinapril were on the opposite sites of linear relationship. Quinapril 221-230 angiotensin I converting enzyme Homo sapiens 185-188 19334497-1 2009 AIM: To investigate antihypertensive efficacy, effects on endothelial, diastolic function of the left ventricle and metabolism of combination of ACE inhibitor quinapril (accupro) with diuretic indapamide SR in patients with hypertension of the second-third degree and type 2 diabetes mellitus (DM) and free of DM. Quinapril 159-168 angiotensin I converting enzyme Homo sapiens 145-148 20634797-2 2010 We evaluated the hypothesis that in patients with chronic heart failure (CHF) and activated cardiac renin-angiotensin-aldosterone system (RAAS), lipophilic ACE inhibitors with high affinity for ACE (perindopril and quinapril) will cause marked blockade of cardiac angiotensin (Ang) II and aldosterone generation, but not a hydrophilic ACE inhibitor with low affinity for ACE (lisinopril). Quinapril 215-224 angiotensin I converting enzyme Homo sapiens 156-159 20634797-2 2010 We evaluated the hypothesis that in patients with chronic heart failure (CHF) and activated cardiac renin-angiotensin-aldosterone system (RAAS), lipophilic ACE inhibitors with high affinity for ACE (perindopril and quinapril) will cause marked blockade of cardiac angiotensin (Ang) II and aldosterone generation, but not a hydrophilic ACE inhibitor with low affinity for ACE (lisinopril). Quinapril 215-224 angiotensin I converting enzyme Homo sapiens 194-197 20634797-2 2010 We evaluated the hypothesis that in patients with chronic heart failure (CHF) and activated cardiac renin-angiotensin-aldosterone system (RAAS), lipophilic ACE inhibitors with high affinity for ACE (perindopril and quinapril) will cause marked blockade of cardiac angiotensin (Ang) II and aldosterone generation, but not a hydrophilic ACE inhibitor with low affinity for ACE (lisinopril). Quinapril 215-224 angiotensin I converting enzyme Homo sapiens 194-197 20634797-2 2010 We evaluated the hypothesis that in patients with chronic heart failure (CHF) and activated cardiac renin-angiotensin-aldosterone system (RAAS), lipophilic ACE inhibitors with high affinity for ACE (perindopril and quinapril) will cause marked blockade of cardiac angiotensin (Ang) II and aldosterone generation, but not a hydrophilic ACE inhibitor with low affinity for ACE (lisinopril). Quinapril 215-224 angiotensin I converting enzyme Homo sapiens 194-197 17917517-2 2007 The patients were treated in a crossover fashion with placebo and the angiotensin-converting enzyme inhibitor quinapril for 24 weeks each. Quinapril 110-119 angiotensin I converting enzyme Homo sapiens 70-99 17928625-11 2007 This study revealed significant benefit of a pharmacological restenosis regimen using the AT(1)-receptor antagonist candesartan in patients with severe atherosclerosis after superficial femoral artery stenting compared with treatment with the ACE inhibitor quinapril. Quinapril 257-266 angiotensin I converting enzyme Homo sapiens 243-246 16765977-1 2006 In this study, the interaction of the anion of quinapril (QUIN), angiotensin converting enzyme (ACE) inhibitor, with cationic surfactant cetyltrimethylammonium bromide (CTAB) was investigated. Quinapril 47-56 angiotensin I converting enzyme Homo sapiens 96-99 17404826-4 2007 CONCLUSION: Quinapril, which is a potent and selective inhibitor of both plasma and tissue ACE, has demonstrated anti-inflammatory properties in many disease states such as atherosclerosis, nephritis, scleroderma, diabetes and arthritis, and, thus, offers new therapeutic possibilities for disease treatment. Quinapril 12-21 angiotensin I converting enzyme Homo sapiens 91-94 17205927-2 2006 Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 57-60 16765977-1 2006 In this study, the interaction of the anion of quinapril (QUIN), angiotensin converting enzyme (ACE) inhibitor, with cationic surfactant cetyltrimethylammonium bromide (CTAB) was investigated. Quinapril 58-62 angiotensin I converting enzyme Homo sapiens 96-99 16191467-1 2005 Quinapril, the active ingredient in Accupril tablets, is an ACE inhibitor used to treat hypertension. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 60-63 16487914-16 2006 In one out of these 6 patients, in whom doxazosin was associated to the ACE inhibitor quinapril, adverse reaction (peripheral edema) led to treatment withdrawal. Quinapril 86-95 angiotensin I converting enzyme Homo sapiens 72-75 16781228-0 2006 Angiotensin-converting enzyme inhibition in patients with coronary artery disease and preserved left ventricular function Ischemia Management with Accupril post-bypass graft via inhibition of angiotensin-converting enzyme (IMAGINE) compared with the other major trials in coronary artery disease. Quinapril 147-155 angiotensin I converting enzyme Homo sapiens 0-29 16781228-0 2006 Angiotensin-converting enzyme inhibition in patients with coronary artery disease and preserved left ventricular function Ischemia Management with Accupril post-bypass graft via inhibition of angiotensin-converting enzyme (IMAGINE) compared with the other major trials in coronary artery disease. Quinapril 147-155 angiotensin I converting enzyme Homo sapiens 192-221 16191467-1 2005 Quinapril, the active ingredient in Accupril tablets, is an ACE inhibitor used to treat hypertension. Quinapril 36-44 angiotensin I converting enzyme Homo sapiens 60-63 15353612-0 2005 The non-thiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis. Quinapril 54-63 angiotensin I converting enzyme Homo sapiens 14-43 16265685-12 2005 ACE inhibition with daily 10 mg quinapril was found to have no significant effects on inflammatory markers and endothelial vasodilator response. Quinapril 32-41 angiotensin I converting enzyme Homo sapiens 0-3 15353612-3 2005 Here we investigated the capacity of the ACE inhibitor quinapril to modulate inflammatory arthritis. Quinapril 55-64 angiotensin I converting enzyme Homo sapiens 41-44 14680725-1 2003 OBJECTIVES: We sought to determine whether angiotensin-converting enzyme inhibition (ACE-I) (i.e., quinapril) prevents transient ischemia (exertional and spontaneous) in patients with coronary artery disease (CAD). Quinapril 99-108 angiotensin I converting enzyme Homo sapiens 43-72 15342298-2 2004 The present trial explored the effects of 2 ACE inhibitors after acute myocardial infarction and found no difference in endothelin-1 production but a greater increase in the production of total nitric oxide with quinapril than with enalapril. Quinapril 212-221 angiotensin I converting enzyme Homo sapiens 44-47 15526248-0 2004 Vascular effects of quinapril completely depend on ACE insertion/deletion polymorphism. Quinapril 20-29 angiotensin I converting enzyme Homo sapiens 51-54 15526248-3 2004 MATERIALS AND METHODS: In the randomised, double-blind QUinapril On Vascular ACE and Determinants of Ischemia Study (QUO VADIS), 149 patients undergoing coronary bypass surgery were randomised to receive either the ACE inhibitor, quinapril, or placebo. Quinapril 55-64 angiotensin I converting enzyme Homo sapiens 77-80 15220251-0 2004 Quinapril, an ACE inhibitor, reduces markers of oxidative stress in the metabolic syndrome. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 14-17 15220251-2 2004 We sought to determine whether the ACE inhibitor quinapril regulates markers of oxidative stress in the metabolic syndrome. Quinapril 49-58 angiotensin I converting enzyme Homo sapiens 35-38 15220251-3 2004 RESEARCH DESIGN AND METHODS: Forty patients with the metabolic syndrome were randomized in a double-blind manner to either the ACE inhibitor quinapril (20 mg/day) or matching placebo for 4 weeks. Quinapril 141-150 angiotensin I converting enzyme Homo sapiens 127-130 15220251-9 2004 CONCLUSIONS: The addition of the ACE inhibitor quinapril reduces markers of vascular oxidative stress and may attenuate the progression of the pathophysiology seen in the metabolic syndrome. Quinapril 47-56 angiotensin I converting enzyme Homo sapiens 33-36 15117912-2 2004 Data collected during a clinical trial that evaluated rapidity of medication up-titration with blood pressure response to monotherapy with the angiotensin-converting enzyme (ACE) inhibitor quinapril were used to characterize response in 533 black and 2046 white participants. Quinapril 189-198 angiotensin I converting enzyme Homo sapiens 174-177 14984622-1 2004 Presented is an unusual case of a 66-year-old-resident of a long-term care facility, who manifested severe dysgeusia and impaired quality of life attributed to the angiotensin-converting enzyme (ACE) inhibitor enalapril; not realized at the time was the fact that he had an adverse reaction-cough-just weeks earlier from another ACE inhibitor in the same class, quinapril, thus illustrating different adverse effects to two antihypertensives in the same class. Quinapril 362-371 angiotensin I converting enzyme Homo sapiens 164-193 12808303-1 2003 Objective of the present study was to investigate the elimination kinetics of quinaprilat and perindoprilat, the active metabolites of angiotensin-converting enzyme (ACE) inhibitors quinapril and perindopril, in hypertensive patients with renal failure under haemodialysis to evaluate the appropriate duration of off-dose of these drugs before starting of low-density lipoprotein (LDL) apheresis. Quinapril 78-87 angiotensin I converting enzyme Homo sapiens 135-164 12808303-1 2003 Objective of the present study was to investigate the elimination kinetics of quinaprilat and perindoprilat, the active metabolites of angiotensin-converting enzyme (ACE) inhibitors quinapril and perindopril, in hypertensive patients with renal failure under haemodialysis to evaluate the appropriate duration of off-dose of these drugs before starting of low-density lipoprotein (LDL) apheresis. Quinapril 78-87 angiotensin I converting enzyme Homo sapiens 166-169 12616664-0 2003 Pharmacokinetics of quinapril in children: assessment during substitution for chronic angiotensin-converting enzyme inhibitor treatment. Quinapril 20-29 angiotensin I converting enzyme Homo sapiens 86-115 12975595-1 2003 UNLABELLED: This double-blind, placebo-controlled study evaluated the effects of the ACE inhibitor, quinapril, on the functional status of elderly frail heart failure patients with preserved systolic function. Quinapril 100-109 angiotensin I converting enzyme Homo sapiens 85-88 12464983-0 2002 Ischemia Management with Accupril post bypass Graft via Inhibition of angiotensin coNverting enzyme (IMAGINE): a multicentre randomized trial - design and rationale. Quinapril 25-33 angiotensin I converting enzyme Homo sapiens 70-99 12652958-1 2003 AIM: To assess effectiveness of ACE inhibitor quinapril in patients with moderate cardiac failure of ischemic etiology. Quinapril 46-55 angiotensin I converting enzyme Homo sapiens 32-35 12149661-9 2002 In hypertensive patients, treatment with the ACE inhibitor quinapril resulted in a significant decrease in endothelin-1 levels. Quinapril 59-68 angiotensin I converting enzyme Homo sapiens 45-48 14728069-3 2003 Evidence from animal studies shows similar and significant (p < 0.05) reductions in tissue ACE activity for moexipril and quinapril. Quinapril 125-134 angiotensin I converting enzyme Homo sapiens 94-97 12464983-6 2002 OBJECTIVE: The Ischemia Management with Accupril post bypass Graft via Inhibition of angiotensin coNverting Enzyme (IMAGINE) study addressed whether ACE inhibition initiated early after CABG improves short and long term outcomes in patients after CABG. Quinapril 40-48 angiotensin I converting enzyme Homo sapiens 85-114 12464983-6 2002 OBJECTIVE: The Ischemia Management with Accupril post bypass Graft via Inhibition of angiotensin coNverting Enzyme (IMAGINE) study addressed whether ACE inhibition initiated early after CABG improves short and long term outcomes in patients after CABG. Quinapril 40-48 angiotensin I converting enzyme Homo sapiens 149-152 11817979-1 2002 UNLABELLED: Quinapril is rapidly de-esterified after absorption to quinaprilat (the active diacid metabolite), a potent angiotensin converting enzyme (ACE) inhibitor. Quinapril 12-21 angiotensin I converting enzyme Homo sapiens 120-149 11986905-10 2002 This proposal is supported by different clinical trials that have shown that the ACE inhibitors with higher affinity by the tissular ACE, such as quinapril, are the most effective in reversing ED principally by accumulating bradykinin. Quinapril 146-155 angiotensin I converting enzyme Homo sapiens 81-84 11986905-10 2002 This proposal is supported by different clinical trials that have shown that the ACE inhibitors with higher affinity by the tissular ACE, such as quinapril, are the most effective in reversing ED principally by accumulating bradykinin. Quinapril 146-155 angiotensin I converting enzyme Homo sapiens 133-136 11849656-7 2002 The ACE I homozygotes also exhibited beneficial effects of quinapril on larger MLD (P=0.065). Quinapril 59-68 angiotensin I converting enzyme Homo sapiens 4-7 11817979-1 2002 UNLABELLED: Quinapril is rapidly de-esterified after absorption to quinaprilat (the active diacid metabolite), a potent angiotensin converting enzyme (ACE) inhibitor. Quinapril 12-21 angiotensin I converting enzyme Homo sapiens 151-154 11817979-2 2002 Quinapril produces favourable haemodynamic changes, and improves ventricular and endothelial function in patients with various cardiovascular disorders; these effects are mediated through the binding of quinaprilat to both tissue and plasma ACE. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 241-244 11817979-11 2002 The tolerability of quinapril is similar to that of other ACE inhibitors. Quinapril 20-29 angiotensin I converting enzyme Homo sapiens 58-61 11817979-14 2002 CONCLUSION: Quinapril is now firmly established as an effective and well tolerated ACE inhibitor for the treatment of patients with hypertension and congestive heart failure. Quinapril 12-21 angiotensin I converting enzyme Homo sapiens 83-86 11800416-0 2001 Quinapril with high affinity to tissue angiotensin-converting enzyme reduces restenosis after percutaneous transcatheter coronary intervention. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 39-68 11487379-7 2001 Measurements of endothelial function and coagulation were normal before treatment and showed no alteration during the study, except in the expected fall in plasma ACE in the quinapril group. Quinapril 174-183 angiotensin I converting enzyme Homo sapiens 163-166 11487379-8 2001 The results indicate that the ACE inhibitor, quinapril, has a beneficial effect on platelet function unlike the calcium channel blocker, nifedipine. Quinapril 45-54 angiotensin I converting enzyme Homo sapiens 30-33 11800416-2 2001 The present study aimed to determine the effect of quinapril, an ACE inhibitor with high affinity to tissue ACE, on restenosis following coronary intervention. Quinapril 51-60 angiotensin I converting enzyme Homo sapiens 65-68 11800416-2 2001 The present study aimed to determine the effect of quinapril, an ACE inhibitor with high affinity to tissue ACE, on restenosis following coronary intervention. Quinapril 51-60 angiotensin I converting enzyme Homo sapiens 108-111 11208485-12 2001 "Tissue type" ACE-Is, e.g. quinapril or perindopril acted through accumulation of endogenous Bk. Quinapril 27-36 angiotensin I converting enzyme Homo sapiens 14-17 11230836-1 2001 QUinapril on Vascular Ace and Determinants of Ischemia. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 22-25 11325479-8 2001 Cyclization reactions of crystalline and amorphous angiotensin-converting enzyme (ACE) inhibitors (spirapril hydrochloride, quinapril hydrochloride, and moexipril) are presented which investigate mobility and chemical reactivity. Quinapril 124-147 angiotensin I converting enzyme Homo sapiens 51-80 11325479-8 2001 Cyclization reactions of crystalline and amorphous angiotensin-converting enzyme (ACE) inhibitors (spirapril hydrochloride, quinapril hydrochloride, and moexipril) are presented which investigate mobility and chemical reactivity. Quinapril 124-147 angiotensin I converting enzyme Homo sapiens 82-85 11204290-9 2001 CONCLUSIONS: The current study suggests the hypothesis that the ACE-inhibitor quinapril has beneficial effects on vascular function in general, and on insulin-mediated vascular responses, in particular. Quinapril 78-87 angiotensin I converting enzyme Homo sapiens 64-67 11967824-2 2000 In order to assess the role of acute ACE inhibition in this setting, coronary arterial endothelial function was quantified following acute intracoronary administration of the angiotensin-converting enzyme (ACE) inhibitor quinapril. Quinapril 221-230 angiotensin I converting enzyme Homo sapiens 206-209 11190581-2 2000 Recently, the angiotensin converting enzyme (ACE) inhibitor quinapril, which has a high affinity for vascular ACE, has improved endothelial dysfunction in coronary artery disease. Quinapril 60-69 angiotensin I converting enzyme Homo sapiens 14-43 11190581-2 2000 Recently, the angiotensin converting enzyme (ACE) inhibitor quinapril, which has a high affinity for vascular ACE, has improved endothelial dysfunction in coronary artery disease. Quinapril 60-69 angiotensin I converting enzyme Homo sapiens 45-48 11190581-2 2000 Recently, the angiotensin converting enzyme (ACE) inhibitor quinapril, which has a high affinity for vascular ACE, has improved endothelial dysfunction in coronary artery disease. Quinapril 60-69 angiotensin I converting enzyme Homo sapiens 110-113 11967824-10 2000 Treatment with the AT(1)-receptor antagonist losartan led to a slight improvement in microvascular endothelial function, but pre-treatment with losartan blunted the vascular effect of quinapril, suggesting that the combination of ACE inhibition and AT(1)-receptor antagonism may not exert a synergistic benefical impact on the coronary vasculature. Quinapril 184-193 angiotensin I converting enzyme Homo sapiens 230-233 10906624-5 2000 In the effects of QUinapril On Vascular ACE and Determinants of ISchemia (QUO VADIS) study, treatment with the angiotensin-converting enzyme (ACE) inhibitor quinapril was associated with significantly fewer ischemic events than placebo at one year following coronary artery bypass graft surgery. Quinapril 18-27 angiotensin I converting enzyme Homo sapiens 40-43 10906624-5 2000 In the effects of QUinapril On Vascular ACE and Determinants of ISchemia (QUO VADIS) study, treatment with the angiotensin-converting enzyme (ACE) inhibitor quinapril was associated with significantly fewer ischemic events than placebo at one year following coronary artery bypass graft surgery. Quinapril 18-27 angiotensin I converting enzyme Homo sapiens 111-140 10906624-5 2000 In the effects of QUinapril On Vascular ACE and Determinants of ISchemia (QUO VADIS) study, treatment with the angiotensin-converting enzyme (ACE) inhibitor quinapril was associated with significantly fewer ischemic events than placebo at one year following coronary artery bypass graft surgery. Quinapril 18-27 angiotensin I converting enzyme Homo sapiens 142-145 10906624-5 2000 In the effects of QUinapril On Vascular ACE and Determinants of ISchemia (QUO VADIS) study, treatment with the angiotensin-converting enzyme (ACE) inhibitor quinapril was associated with significantly fewer ischemic events than placebo at one year following coronary artery bypass graft surgery. Quinapril 157-166 angiotensin I converting enzyme Homo sapiens 40-43 10906624-5 2000 In the effects of QUinapril On Vascular ACE and Determinants of ISchemia (QUO VADIS) study, treatment with the angiotensin-converting enzyme (ACE) inhibitor quinapril was associated with significantly fewer ischemic events than placebo at one year following coronary artery bypass graft surgery. Quinapril 157-166 angiotensin I converting enzyme Homo sapiens 111-140 10906624-5 2000 In the effects of QUinapril On Vascular ACE and Determinants of ISchemia (QUO VADIS) study, treatment with the angiotensin-converting enzyme (ACE) inhibitor quinapril was associated with significantly fewer ischemic events than placebo at one year following coronary artery bypass graft surgery. Quinapril 157-166 angiotensin I converting enzyme Homo sapiens 142-145 10784227-0 2000 Angiotensin-converting enzyme inhibition by quinapril blocks the albuminuric effect of atrial natriuretic peptide in Type 1 diabetes and microalbuminuria. Quinapril 44-53 angiotensin I converting enzyme Homo sapiens 0-29 23315349-8 2000 In hypertensive patients with diabetes mellitus (n = 1269) and in patients previously treated with other ACE inhibitors (n = 2083), quinapril therapy was also associated with statistically significant decreases in mean DBP and SBP (p < 0.0001). Quinapril 132-141 angiotensin I converting enzyme Homo sapiens 105-108 10755201-2 2000 The QUO VADIS (the effects of QUinapril On Vascular Ace and Determinants of ISchemia) study was a randomized, double-blind, placebo-controlled trial designed to evaluate the effects of long-term angiotensin-converting enzyme (ACE) inhibition on angiotensin II formation in human vasculature. Quinapril 30-39 angiotensin I converting enzyme Homo sapiens 52-55 10072217-7 1999 Thus, ACE inhibitor therapy with quinapril selectively improves endothelium-dependent vasodilator responsiveness by increased NO bioactivity in relation to vascular smooth muscle in patients with coronary artery disease, an effect achieved at a lower rate of NO release from the endothelium. Quinapril 33-42 angiotensin I converting enzyme Homo sapiens 6-9 10636260-1 2000 BACKGROUND: Quinapril, an ACE inhibitor with high affinity, has been shown to improve coronary endothelial dysfunction in patients with coronary artery disease. Quinapril 12-21 angiotensin I converting enzyme Homo sapiens 26-29 10636260-13 2000 CONCLUSION: Only quinapril was associated with significant improvement in FMD, and this response is related to the presence of the insertion allele of the ACE genotype. Quinapril 17-26 angiotensin I converting enzyme Homo sapiens 155-158 10350682-2 1999 Only quinapril, which is a lipophilic ACE inhibitor with high affinity for tissue ACE, produced a significant improvement in flow-mediated brachial artery dilation in coronary artery disease patients; enalapril, losartan and amlodipine did not. Quinapril 5-14 angiotensin I converting enzyme Homo sapiens 38-41 10350682-2 1999 Only quinapril, which is a lipophilic ACE inhibitor with high affinity for tissue ACE, produced a significant improvement in flow-mediated brachial artery dilation in coronary artery disease patients; enalapril, losartan and amlodipine did not. Quinapril 5-14 angiotensin I converting enzyme Homo sapiens 82-85 10082500-4 1999 Therefore, the goal of this double-blind, randomized study was to compare the antihypertensive and renal effects of the ACE inhibitor quinapril with those of the beta-blocker atenolol in renal allograft recipients in whom hypertension developed 6 to 12 weeks after transplantation. Quinapril 134-143 angiotensin I converting enzyme Homo sapiens 120-123 10439882-3 1999 Our study evaluated the influence of smoking status on coronary endothelial function in normotensive patients with coronary artery disease who received placebo or the angiotensin-converting enzyme inhibitor quinapril in the TREND study (Trial on Reversing Endothelial Dysfunction). Quinapril 207-216 angiotensin I converting enzyme Homo sapiens 167-196 10350682-3 1999 Quinapril showed highly significant improvement in subjects with one copy of the insertion allele, either the ACE-ID or the ACE-II genotype. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 110-113 10350682-3 1999 Quinapril showed highly significant improvement in subjects with one copy of the insertion allele, either the ACE-ID or the ACE-II genotype. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 124-127 10350682-4 1999 It is anticipated that the effects of QUinapril On Vascular ACE and Determinants of ISchemia (QUO VADIS) trial will further differentiate ACE inhibitors (quinapril versus captopril) according to their effects on vascular tissue taken from pretreated patients undergoing coronary artery bypass graft surgery. Quinapril 38-47 angiotensin I converting enzyme Homo sapiens 60-63 10350682-4 1999 It is anticipated that the effects of QUinapril On Vascular ACE and Determinants of ISchemia (QUO VADIS) trial will further differentiate ACE inhibitors (quinapril versus captopril) according to their effects on vascular tissue taken from pretreated patients undergoing coronary artery bypass graft surgery. Quinapril 38-47 angiotensin I converting enzyme Homo sapiens 138-141 10350682-4 1999 It is anticipated that the effects of QUinapril On Vascular ACE and Determinants of ISchemia (QUO VADIS) trial will further differentiate ACE inhibitors (quinapril versus captopril) according to their effects on vascular tissue taken from pretreated patients undergoing coronary artery bypass graft surgery. Quinapril 154-163 angiotensin I converting enzyme Homo sapiens 138-141 9717054-5 1998 Available results suggest that ACE inhibition with quinapril improves endothelial function in large and small vessels in patients with coronary artery disease and preserved left ventricular function. Quinapril 51-60 angiotensin I converting enzyme Homo sapiens 31-34 9364284-2 1997 Both markers were raised in the patients (P < 0.05), and in a subgroup of patients, beta thromboglobulin was reduced with successful treatment of hypertension with the ACE inhibitor quinapril. Quinapril 185-194 angiotensin I converting enzyme Homo sapiens 171-174 9579768-3 1998 In a randomised, double-blind crossover trial, we used the ACE inhibitor quinapril as a marker to evaluate the changes in: pulse pressure amplification (applanation tonometry), carotid compliance and distensibility (echo-tracking technique), and aortic distensibility (measured from pulse wave velocity). Quinapril 73-82 angiotensin I converting enzyme Homo sapiens 59-62 9504729-1 1998 OBJECTIVE: To investigate the effect of 6 weeks" pre-operative treatment with the angiotensin converting enzyme inhibitor, quinapril, on left ventricular function when measured 3 months after coronary artery bypass graft surgery and to examine the safety of such treatment. Quinapril 123-132 angiotensin I converting enzyme Homo sapiens 82-111 9140710-1 1997 The short-term effects of administration of an angiotensin-converting enzyme (ACE) inhibitor, quinapril hydrochloride (quinapril) (5-10 mg/day), for 12 weeks on blood pressure and renal function were evaluated in 8 patients (60.5 +/- 7.3 years old, mean +/- SD) with mild to moderate essential hypertension and mild impairment of renal function due to nephrosclerosis. Quinapril 94-103 angiotensin I converting enzyme Homo sapiens 78-81 9008252-1 1997 In this study, we investigated whether antihypertensive treatment with the angiotensin converting enzyme inhibitor quinapril modifies Na+/H+ exchanger activity or NHE-1 (isoform of the exchanger) mRNA expression in lymphocytes from patients with essential hypertension. Quinapril 115-124 angiotensin I converting enzyme Homo sapiens 75-104 9051387-3 1997 RESEARCH DESIGN AND METHODS: The present double-blind, randomized, and placebo-controlled study analyzed the effect of quinapril, an ACE inhibitor, on HRV time and frequency domain variables in patients with DAN. Quinapril 119-128 angiotensin I converting enzyme Homo sapiens 133-136 7874846-5 1994 The main purpose of the present study was to investigate, in normal human subjects, the effect of the angiotensin-converting enzyme inhibitor quinapril on plasma kinins. Quinapril 142-151 angiotensin I converting enzyme Homo sapiens 102-131 9049526-2 1997 UNLABELLED: RATIONALE AND STUDY DESIGN: This study assesses safety and efficacy when hypertensive patients convert from an oral angiotensin converting enzyme inhibitor, quinapril, to its intravenous counterpart, quinaprilat, and evaluates the need for short-term conversion from oral to parenteral therapy. Quinapril 169-178 angiotensin I converting enzyme Homo sapiens 128-157 9049577-0 1997 Effect of enalapril and quinapril on forearm vascular ACE in man. Quinapril 24-33 angiotensin I converting enzyme Homo sapiens 54-57 9049577-2 1997 Quinapril appears to be amongst the more effective inhibitors of vascular tissue ACE in vitro. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 81-84 9049577-3 1997 This study assesses the in vivo effect of single oral doses of quinapril and enalapril, in attenuating the vasoconstrictive action of angiotensin I (AI) (which we have previously shown depends on its conversion to angiotensin II (AII) by vascular ACE) in the forearm resistance vessels of man. Quinapril 63-72 angiotensin I converting enzyme Homo sapiens 247-250 9049577-7 1997 Both quinapril and enalapril produced a similar degree of plasma ACE inhibition reducing concentrations to 2.8 U.l-1 and 2.6 U.l-1 respectively. Quinapril 5-14 angiotensin I converting enzyme Homo sapiens 65-68 9049577-10 1997 CONCLUSION: These results indicate that when quinapril and enalapril are administered as single 20 mg doses, each of which produces the same degree of plasma ACE inhibition and blood pressure reduction- quinapril inhibits vascular ACE to a greater degree than both enalapril and placebo. Quinapril 45-54 angiotensin I converting enzyme Homo sapiens 158-161 9049577-10 1997 CONCLUSION: These results indicate that when quinapril and enalapril are administered as single 20 mg doses, each of which produces the same degree of plasma ACE inhibition and blood pressure reduction- quinapril inhibits vascular ACE to a greater degree than both enalapril and placebo. Quinapril 45-54 angiotensin I converting enzyme Homo sapiens 231-234 9049577-10 1997 CONCLUSION: These results indicate that when quinapril and enalapril are administered as single 20 mg doses, each of which produces the same degree of plasma ACE inhibition and blood pressure reduction- quinapril inhibits vascular ACE to a greater degree than both enalapril and placebo. Quinapril 203-212 angiotensin I converting enzyme Homo sapiens 231-234 9064945-5 1996 Quinaprilat is the active metabolite of quinapril, an ACE inhibitor with high affinity for the angiotensin converting enzyme, which is formulated for oral application. Quinapril 40-49 angiotensin I converting enzyme Homo sapiens 54-57 9064945-5 1996 Quinaprilat is the active metabolite of quinapril, an ACE inhibitor with high affinity for the angiotensin converting enzyme, which is formulated for oral application. Quinapril 40-49 angiotensin I converting enzyme Homo sapiens 95-124 8894262-3 1996 Consequently, we designed a double-blind 12-week trial comparing the new angiotensin-converting enzyme (ACE) inhibitor, quinapril (n = 5,053), with a well-established beta-adrenergic receptor blocker, metoprolol (n = 506). Quinapril 120-129 angiotensin I converting enzyme Homo sapiens 104-107 8986916-2 1996 DESIGN AND METHODS: Twelve hypertensive patients with ESRD were included in a double-blind, cross-over study comparing a single 20 mg dose of the ACE inhibitor quinapril versus placebo. Quinapril 160-169 angiotensin I converting enzyme Homo sapiens 146-149 8759064-0 1996 Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Quinapril 46-55 angiotensin I converting enzyme Homo sapiens 0-29 8759064-8 1996 CONCLUSIONS: TREND shows that ACE inhibition with quinapril improved endothelial dysfunction in patients who were normotensive and who did not have severe hyperlipidemia or evidence of heart failure. Quinapril 50-59 angiotensin I converting enzyme Homo sapiens 30-33 8743525-0 1996 Quinapril ACE-inhibition effects on adrenergic parameters in moderate essential hypertension. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 10-13 8743525-2 1996 Plasmatic renin activity, catecolamines, and aldosterone as well as vascular reactivity after norepinephrine and angiotensin II perfusion were determined before and after treatment with the ACE inhibitor quinapril up to 40 mg/day during four months. Quinapril 204-213 angiotensin I converting enzyme Homo sapiens 190-193 7576397-1 1995 To investigate the metabolic and renal effects of the nonsulfhydryl, tissue-active ACE inhibitor quinapril in diabetes and in hypertension, we studied 30 essential hypertensives and 24 non-insulin-dependent (type II) diabetic (NIDDM) subjects with hypertension. Quinapril 97-106 angiotensin I converting enzyme Homo sapiens 83-86 7712932-1 1995 The effect on myocardial function and structure of long-term administration of quinapril (10-20 mg daily), an angiotensin-converting-enzyme (ACE) inhibitor, was investigated in 24 patients (18 men, 6 women; mean age 48 [20-65] years) with chronic isolated asymptomatic aortic or mitral regurgitation. Quinapril 79-88 angiotensin I converting enzyme Homo sapiens 110-139 7712932-1 1995 The effect on myocardial function and structure of long-term administration of quinapril (10-20 mg daily), an angiotensin-converting-enzyme (ACE) inhibitor, was investigated in 24 patients (18 men, 6 women; mean age 48 [20-65] years) with chronic isolated asymptomatic aortic or mitral regurgitation. Quinapril 79-88 angiotensin I converting enzyme Homo sapiens 141-144 7713100-0 1994 Dose-related effects of ACE inhibition in man: quinapril in patients with moderate congestive heart failure. Quinapril 47-56 angiotensin I converting enzyme Homo sapiens 24-27 7713100-9 1994 Chronic inhibition of ACE activity was dose-dependent and the maximal fall in Ang II occurred with quinapril 20 mg.day-1. Quinapril 99-108 angiotensin I converting enzyme Homo sapiens 22-25 7981011-16 1994 Compared with placebo, quinapril 2.5 mg inhibits plasma ACE by over 60% for 24 h and reduces blood pressure for at least 10 h in patients with stable, chronic congestive heart failure. Quinapril 23-32 angiotensin I converting enzyme Homo sapiens 56-59 7965273-2 1994 METHODS: Structural and functional changes in the heart and iliac artery were studied by echocardiography and intraluminal ultrasound in 15 hypertensive patients following 6 months of treatment with the ACE inhibitor quinapril at 10-40 mg/day. Quinapril 217-226 angiotensin I converting enzyme Homo sapiens 203-206 7965277-7 1994 Other ongoing studies such as the QUinapril Ischemic Event Trial (QUIET) are assessing ACE inhibitor effects in patients with coronary artery disease and a normal left ventricular function. Quinapril 34-43 angiotensin I converting enzyme Homo sapiens 87-90 7965280-3 1994 PATIENTS AND METHODS: Twenty-four patients with isolated moderate to severe chronic aortic regurgitation or mitral regurgitation who were free of coronary disease were studied before treatment (control) with the ACE inhibitor quinapril and were then followed for 1 year during quinapril therapy (10-20 mg/day). Quinapril 226-235 angiotensin I converting enzyme Homo sapiens 212-215 7919557-1 1994 OBJECTIVE: To report a case of chronic, nonproductive cough secondary to the angiotensin-converting enzyme (ACE) inhibitor quinapril, with complete resolution after switching to another ACE inhibitor, fosinopril. Quinapril 123-132 angiotensin I converting enzyme Homo sapiens 186-189 7919557-13 1994 We report a case of cough following the administration of quinapril, with complete resolution after changing to the alternative ACE inhibitor fosinopril in a patient with essential hypertension. Quinapril 58-67 angiotensin I converting enzyme Homo sapiens 128-131 8087269-3 1994 Therefore the aim of this study was to assess the effects of one year angiotensin-converting enzyme inhibition with quinapril on myocardial performance in patients with chronic mitral regurgitation. Quinapril 116-125 angiotensin I converting enzyme Homo sapiens 70-99 8087269-9 1994 In conclusion, in patients with chronic mitral regurgitation long term angiotensin-converting enzyme inhibition with quinapril reduces regurgitation and decreases left ventricular size and mass thereby demonstrating functional improvement. Quinapril 117-126 angiotensin I converting enzyme Homo sapiens 71-100 8739020-1 1996 Quinaprilat is the active metabolite of quinapril, an orally active angiotensin-converting enzyme (ACE) inhibitor. Quinapril 40-49 angiotensin I converting enzyme Homo sapiens 68-97 8739020-1 1996 Quinaprilat is the active metabolite of quinapril, an orally active angiotensin-converting enzyme (ACE) inhibitor. Quinapril 40-49 angiotensin I converting enzyme Homo sapiens 99-102 7805197-4 1995 METHODS AND RESULTS: In the present study, we assessed the effects of ACE inhibitors with low (enalapril) and high (quinapril) affinity for cardiac tissue ACE on prevention of volume overload-induced cardiac hypertrophy in relation to their hemodynamic effects. Quinapril 116-125 angiotensin I converting enzyme Homo sapiens 155-158 7807504-0 1994 Speed and duration of dose titration with the angiotensin converting enzyme inhibitor quinapril: relationship with efficacy in patients with moderate hypertension. Quinapril 86-95 angiotensin I converting enzyme Homo sapiens 46-75 8000584-1 1994 This study was performed to assess the effects of one year of ACE inhibition with quinapril on left ventricular performance and morphology in asymptomatic patients with chronic aortic regurgitation. Quinapril 82-91 angiotensin I converting enzyme Homo sapiens 62-65 7527326-2 1994 Following systemic absorption, quinapril is converted by de-esterification to quinaprilat (the active diacid metabolite), an inhibitor of angiotensin converting enzyme (ACE). Quinapril 31-40 angiotensin I converting enzyme Homo sapiens 138-167 7527326-2 1994 Following systemic absorption, quinapril is converted by de-esterification to quinaprilat (the active diacid metabolite), an inhibitor of angiotensin converting enzyme (ACE). Quinapril 31-40 angiotensin I converting enzyme Homo sapiens 169-172 7527326-3 1994 Pharmacodynamic studies in animals indicate inhibition of ACE both in plasma and at tissue sites, such as the arterial wall and heart, following administration of quinapril. Quinapril 163-172 angiotensin I converting enzyme Homo sapiens 58-61 7527326-4 1994 Tissue ACE inhibition may be an important component of the mechanism of action of quinapril (and other ACE inhibitors) in achieving favourable effects in cardiovascular disorders. Quinapril 82-91 angiotensin I converting enzyme Homo sapiens 7-10 7527326-4 1994 Tissue ACE inhibition may be an important component of the mechanism of action of quinapril (and other ACE inhibitors) in achieving favourable effects in cardiovascular disorders. Quinapril 82-91 angiotensin I converting enzyme Homo sapiens 103-106 7919557-1 1994 OBJECTIVE: To report a case of chronic, nonproductive cough secondary to the angiotensin-converting enzyme (ACE) inhibitor quinapril, with complete resolution after switching to another ACE inhibitor, fosinopril. Quinapril 123-132 angiotensin I converting enzyme Homo sapiens 77-106 7919557-1 1994 OBJECTIVE: To report a case of chronic, nonproductive cough secondary to the angiotensin-converting enzyme (ACE) inhibitor quinapril, with complete resolution after switching to another ACE inhibitor, fosinopril. Quinapril 123-132 angiotensin I converting enzyme Homo sapiens 108-111 1630680-2 1992 The efficacy and safety of the treatment of arterial hypertension with the ACE-inhibitor quinapril, were evaluated in a multicentre study conducted in Italy. Quinapril 89-98 angiotensin I converting enzyme Homo sapiens 75-78 7769502-1 1994 OBJECTIVE: To evaluate the efficacy and duration of action of the angiotensin converting enzyme inhibitor quinapril hydrochloride by using ambulatory blood pressure monitoring. Quinapril 106-129 angiotensin I converting enzyme Homo sapiens 66-95 8462229-17 1993 Other ACE inhibitors, such as quinapril or cilazapril, are only poorly eliminated by haemodialysis or peritoneal dialysis. Quinapril 30-39 angiotensin I converting enzyme Homo sapiens 6-9 1451252-4 1992 The patients were studied without any pretreatment (n = 14) or after 1 week of treatment with the oral ACE inhibitor quinapril at a dosage of 10 mg/day (n = 11). Quinapril 117-126 angiotensin I converting enzyme Homo sapiens 103-106 1451252-13 1992 CONCLUSIONS: We conclude that pretreatment with the ACE inhibitor quinapril significantly improves compromised responses to acute isotonic volume overload in patients with dilated cardiomyopathy and mild heart failure. Quinapril 66-75 angiotensin I converting enzyme Homo sapiens 52-55 1385791-5 1992 Quinapril (CI 906, Malesci, Florence, Italy), an ACE inhibitor without sulfhydryl group. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 49-52 1615796-1 1992 The objective of the present study was to determine whether pretreatment neurohormonal and renal hemodynamic parameters predict the change in renal function with the administration of quinapril, a new angiotensin-converting enzyme (ACE) inhibitor. Quinapril 184-193 angiotensin I converting enzyme Homo sapiens 201-230 1575168-4 1992 An ACE inhibitor such as quinapril that has a comparatively short plasma concentration half-life binds strongly to plasma ACE as well as to ACE in key tissues including artery wall, heart, and kidney. Quinapril 25-34 angiotensin I converting enzyme Homo sapiens 3-6 1575168-4 1992 An ACE inhibitor such as quinapril that has a comparatively short plasma concentration half-life binds strongly to plasma ACE as well as to ACE in key tissues including artery wall, heart, and kidney. Quinapril 25-34 angiotensin I converting enzyme Homo sapiens 122-125 1575168-4 1992 An ACE inhibitor such as quinapril that has a comparatively short plasma concentration half-life binds strongly to plasma ACE as well as to ACE in key tissues including artery wall, heart, and kidney. Quinapril 25-34 angiotensin I converting enzyme Homo sapiens 122-125 1575171-1 1992 Effects of the angiotensin-converting enzyme inhibitor quinapril. Quinapril 55-64 angiotensin I converting enzyme Homo sapiens 15-44 1575171-2 1992 Clinical studies indicate that the angiotensin-converting enzyme inhibitor quinapril is an effective antihypertensive agent when administered once daily. Quinapril 75-84 angiotensin I converting enzyme Homo sapiens 35-64 1575171-6 1992 The blood pressure reduction in patients with mild hypertension receiving long-term quinapril therapy may be more closely related to prolonged angiotensin-converting enzyme inhibition or to an effect on tissue angiotensin II concentration than to the plasma half-life. Quinapril 84-93 angiotensin I converting enzyme Homo sapiens 143-172 1312296-4 1992 The blood pressure-lowering effect of quinapril, for example, correlated better with inhibition of tissue ACE (aorta) than with inhibition of plasma ACE. Quinapril 38-47 angiotensin I converting enzyme Homo sapiens 106-109 1312296-4 1992 The blood pressure-lowering effect of quinapril, for example, correlated better with inhibition of tissue ACE (aorta) than with inhibition of plasma ACE. Quinapril 38-47 angiotensin I converting enzyme Homo sapiens 149-152 1312296-6 1992 Newer ACE inhibitors, such as quinapril, have favorable side effect profiles as well as apparent tissue specificity for the vascular renin-angiotensin system (and possibly other relevant cardiovascular tissue). Quinapril 30-39 angiotensin I converting enzyme Homo sapiens 6-9 1312002-0 1992 Dose responses and pharmacokinetics for the angiotensin converting enzyme inhibitor quinapril. Quinapril 84-93 angiotensin I converting enzyme Homo sapiens 44-73 1312002-1 1992 Single doses of the angiotensin converting enzyme (ACE) inhibitor quinapril were administered to salt replete normotensive men to investigate pharmacokinetics and dose responses. Quinapril 66-75 angiotensin I converting enzyme Homo sapiens 20-49 1312002-1 1992 Single doses of the angiotensin converting enzyme (ACE) inhibitor quinapril were administered to salt replete normotensive men to investigate pharmacokinetics and dose responses. Quinapril 66-75 angiotensin I converting enzyme Homo sapiens 51-54 1312002-5 1992 These findings suggest that quinapril displays the same prolonged terminal phase half-life that is characteristic of other ACE inhibitor drugs. Quinapril 28-37 angiotensin I converting enzyme Homo sapiens 123-126 1366232-0 1992 [Cardiovascular profile of the ACE-inhibitor Quinapril. Quinapril 45-54 angiotensin I converting enzyme Homo sapiens 31-34 2035890-2 1991 The pharmacokinetics and efficacy of captopril, enalapril, and a new once-daily ACE inhibitor, quinapril for the treatment of hypertension in young and elderly patients are reviewed, and the safety profiles of these agents in young and elderly patients are discussed. Quinapril 95-104 angiotensin I converting enzyme Homo sapiens 80-83 8357782-2 1993 QUIET is a prospective, double-blind placebo-controlled study that will assess the ability of the angiotensin-converting enzyme (ACE) inhibitor quinapril to reduce the rate of cardiac ischemic events and to slow or prevent the development of coronary artery atherosclerosis as assessed by serial angiography in a normolipidemic population without left ventricular dysfunction. Quinapril 144-153 angiotensin I converting enzyme Homo sapiens 98-127 8357782-2 1993 QUIET is a prospective, double-blind placebo-controlled study that will assess the ability of the angiotensin-converting enzyme (ACE) inhibitor quinapril to reduce the rate of cardiac ischemic events and to slow or prevent the development of coronary artery atherosclerosis as assessed by serial angiography in a normolipidemic population without left ventricular dysfunction. Quinapril 144-153 angiotensin I converting enzyme Homo sapiens 129-132 8387427-1 1993 The pharmacokinetics and pharmacodynamics of the ACE inhibitor quinaprilat have been studied in six chronic haemodialysis (HD) patients and in six patients undergoing continuous ambulatory peritoneal dialysis (CAPD) after a single oral dose of 2.5 mg quinapril. Quinapril 63-72 angiotensin I converting enzyme Homo sapiens 49-52 7728496-1 1993 ACE-inhibition with Quinapril: hypertension, myocardial infarction, cardiac insufficiency]. Quinapril 20-29 angiotensin I converting enzyme Homo sapiens 0-3 1329465-5 1992 In contrast, drugs requiring biotransformation to active forms, e.g., angiotensin-converting enzyme (ACE) inhibitors such as enalapril, perindopril, quinapril, and ramipril, generally have lower than expected plasma concentrations. Quinapril 149-158 angiotensin I converting enzyme Homo sapiens 70-99 1329465-5 1992 In contrast, drugs requiring biotransformation to active forms, e.g., angiotensin-converting enzyme (ACE) inhibitors such as enalapril, perindopril, quinapril, and ramipril, generally have lower than expected plasma concentrations. Quinapril 149-158 angiotensin I converting enzyme Homo sapiens 101-104 1546636-6 1992 Experiments with quinapril demonstrated that inhibition of vascular ACE was a significant component of the antihypertensive effect of the drug. Quinapril 17-26 angiotensin I converting enzyme Homo sapiens 68-71 1546638-9 1992 Enhanced tissue effects of newer ACE inhibitors such as quinapril may result in improved regional hemodynamic effects. Quinapril 56-65 angiotensin I converting enzyme Homo sapiens 33-36 1546639-0 1992 Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril. Quinapril 102-111 angiotensin I converting enzyme Homo sapiens 19-48 1546639-4 1992 Quinapril is a new ACE inhibitor that is converted to biologically active quinaprilat in the liver. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 19-22 1546639-8 1992 In other studies, headache was reported by up to 4.7% of patients receiving quinapril, which is comparable to reported incidences of headache in patients receiving other ACE inhibitors. Quinapril 76-85 angiotensin I converting enzyme Homo sapiens 170-173 1290245-3 1992 To prove the usefulness of selfrecordings in clinical trials we investigated both selfrecordings taken twice a day and casual readings within intervals of 1 to 3 weeks, in this study on the efficacy and tolerability of the ACE-inhibitor Accupro. Quinapril 237-244 angiotensin I converting enzyme Homo sapiens 223-226 1795202-4 1991 We have recently used ambulatory blood pressure recording to assess the magnitude and duration of the first dose of an angiotensin converting enzyme (ACE) inhibitor, quinapril, compared to placebo. Quinapril 166-175 angiotensin I converting enzyme Homo sapiens 119-148 1795202-4 1991 We have recently used ambulatory blood pressure recording to assess the magnitude and duration of the first dose of an angiotensin converting enzyme (ACE) inhibitor, quinapril, compared to placebo. Quinapril 166-175 angiotensin I converting enzyme Homo sapiens 150-153 1777377-2 1991 The importance of total dose to the initial hypotensive response with an angiotensin converting enzyme inhibitor (quinapril) was assessed using a suggested "maintenance" dose (20 mg) or matched placebo in a randomised double-blind study in patients with uncomplicated hypertension. Quinapril 114-123 angiotensin I converting enzyme Homo sapiens 73-102 1830551-1 1991 The objective of this double-blind, placebo-controlled, randomized multicentre study was to determine whether treatment with the new non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor quinapril, as an addition to maintenance therapy with digitalis and/or diuretics, would improve exercise tolerance and patients" symptomatology over a treatment period of 3 months. Quinapril 194-203 angiotensin I converting enzyme Homo sapiens 148-177 1830551-1 1991 The objective of this double-blind, placebo-controlled, randomized multicentre study was to determine whether treatment with the new non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor quinapril, as an addition to maintenance therapy with digitalis and/or diuretics, would improve exercise tolerance and patients" symptomatology over a treatment period of 3 months. Quinapril 194-203 angiotensin I converting enzyme Homo sapiens 179-182 2068835-0 1991 Quinapril: a new second-generation ACE inhibitor. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 35-38 2068835-1 1991 Quinapril is a new non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 34-63 2068835-1 1991 Quinapril is a new non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 65-68 2068835-3 1991 On a weight basis quinaprilat is three times as potent an ACE inhibitor as quinapril. Quinapril 18-27 angiotensin I converting enzyme Homo sapiens 58-61 1834452-0 1991 More ACE inhibitors--quinapril, perindopril & ramipril. Quinapril 21-30 angiotensin I converting enzyme Homo sapiens 5-8 1711445-2 1991 Quinapril is a monoethyl ester which is hydrolysed after absorption to form an active metabolite, quinaprilat, which is a more potent angiotensin converting enzyme (ACE) inhibitor than the parent drug. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 134-163 1711445-2 1991 Quinapril is a monoethyl ester which is hydrolysed after absorption to form an active metabolite, quinaprilat, which is a more potent angiotensin converting enzyme (ACE) inhibitor than the parent drug. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 165-168 1711445-10 1991 Adverse effects associated with the antihypertensive action of quinapril are generally mild, well tolerated and are similar to those of other ACE inhibitors. Quinapril 63-72 angiotensin I converting enzyme Homo sapiens 142-145 1711445-11 1991 Thus, quinapril appears to be a useful alternative ACE inhibitor for the treatment of mild to severe hypertension and congestive heart failure. Quinapril 6-15 angiotensin I converting enzyme Homo sapiens 51-54 2539762-1 1989 Quinapril is converted to quinaprilat, a long-acting angiotensin converting enzyme (ACE) inhibitor, and is currently being studied for the treatment of hypertension and congestive heart failure. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 84-87 1708046-0 1991 Platelet function during antihypertensive treatment with quinapril, a novel angiotensin converting enzyme inhibitor. Quinapril 57-66 angiotensin I converting enzyme Homo sapiens 76-105 1708046-3 1991 Therefore, the aim of the present study was to examine the effect of antihypertensive treatment with quinapril, a novel ACE inhibitor not containing a sulfhydryl group, on platelet function. Quinapril 101-110 angiotensin I converting enzyme Homo sapiens 120-123 2273086-1 1990 The pharmacokinetics of quinapril, a novel angiotensin converting enzyme (ACE) inhibitor, and its active metabolite, quinaprilat, were determined following a single 20-mg oral dose of quinapril in six patients with chronic renal failure maintained on continuous ambulatory peritoneal dialysis (CAPD). Quinapril 24-33 angiotensin I converting enzyme Homo sapiens 74-77 2226219-9 1990 Many new ACE inhibitors are undergoing clinical assessment, including alacepril, cilazapril, fosenopril, perindopril, quinapril and ramipril. Quinapril 118-127 angiotensin I converting enzyme Homo sapiens 9-12 2189616-1 1990 Quinapril hydrochloride is the newest member of a family of angiotensin-converting enzyme (ACE) inhibitors. Quinapril 0-23 angiotensin I converting enzyme Homo sapiens 60-89 2189616-1 1990 Quinapril hydrochloride is the newest member of a family of angiotensin-converting enzyme (ACE) inhibitors. Quinapril 0-23 angiotensin I converting enzyme Homo sapiens 91-94 2189616-8 1990 Quinapril has also been found to be the most potent of all available ACE inhibitors in binding to tissue ACE, which may contribute to its potent and sustained duration of action. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 69-72 2189616-8 1990 Quinapril has also been found to be the most potent of all available ACE inhibitors in binding to tissue ACE, which may contribute to its potent and sustained duration of action. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 105-108 2189617-1 1990 Major clinical trials are reviewed comparing the efficacy and safety of quinapril hydrochloride, a new nonsulfhydryl angiotensin-converting enzyme (ACE) inhibitor, with that of placebo, captopril, and enalapril in the treatment of mild to moderate essential hypertension. Quinapril 72-95 angiotensin I converting enzyme Homo sapiens 117-146 2189617-1 1990 Major clinical trials are reviewed comparing the efficacy and safety of quinapril hydrochloride, a new nonsulfhydryl angiotensin-converting enzyme (ACE) inhibitor, with that of placebo, captopril, and enalapril in the treatment of mild to moderate essential hypertension. Quinapril 72-95 angiotensin I converting enzyme Homo sapiens 148-151 2193808-4 1990 The new ACE inhibitor quinapril appears to share the haemodynamic effects of other ACE inhibitors with an improvement of cardiovascular function in congestive heart failure. Quinapril 22-31 angiotensin I converting enzyme Homo sapiens 8-11 2193808-4 1990 The new ACE inhibitor quinapril appears to share the haemodynamic effects of other ACE inhibitors with an improvement of cardiovascular function in congestive heart failure. Quinapril 22-31 angiotensin I converting enzyme Homo sapiens 83-86 2193809-6 1990 Quinapril is a new non-sulphydryl ACE inhibitor whose active metabolite, quinaprilat, has a relatively short accumulation half-life compared with enalapril and lisinopril but has an enhanced affinity for the converting enzyme, allowing rapid excretion of the drug while retaining a 24-hour antihypertensive effect with once-daily dosing. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 34-37 2193809-7 1990 Quinapril is a valuable addition to the ACE inhibitor class, with demonstrated efficacy and safety in the older patient. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 40-43 2193811-6 1990 In one preliminary report, monotherapy with the ACE inhibitor quinapril was shown to improve exercise time and functional class in patients with mild heart failure compared to placebo. Quinapril 62-71 angiotensin I converting enzyme Homo sapiens 48-51 34412518-4 2021 Clinical studies on ACE inhibitors mainly focus on their efficacy, although few examine their potential to generate undesirable adverse effects, particularly with regard to angioedema.Case description: We report here a case of angioedema occurring after ramipril initiation in a patient chronically treated with quinapril. Quinapril 312-321 angiotensin I converting enzyme Homo sapiens 20-23 2553899-5 1989 Ex vivo studies showed that after oral administration of quinapril, ACE was inhibited dose-dependently in the lung, kidney, aorta and heart for more than 24h. Quinapril 57-66 angiotensin I converting enzyme Homo sapiens 68-71 2553900-1 1989 The results of more than 1600 patient years of experience with the new angiotensin converting enzyme (ACE) inhibitor, quinapril, suggest that it is safe for the treatment of hypertension and congestive heart failure. Quinapril 118-127 angiotensin I converting enzyme Homo sapiens 71-100 2650581-1 1989 Quinapril HCl is a novel, nonsulfhydryl angiotensin-converting enzyme (ACE) inhibitor. Quinapril 0-13 angiotensin I converting enzyme Homo sapiens 40-69 2650581-1 1989 Quinapril HCl is a novel, nonsulfhydryl angiotensin-converting enzyme (ACE) inhibitor. Quinapril 0-13 angiotensin I converting enzyme Homo sapiens 71-74 2650583-9 1989 Quinapril, a nonsulfhydryl ACE inhibitor, has been extensively studied and is equally well tolerated in the young and elderly for the treatment of hypertension and CHF. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 27-30 2670222-5 1989 Comparative safety data are provided for captopril, enalapril, and quinapril, a new nonsulfhydryl ACE inhibitor that has been investigated extensively in over 2,000 patients. Quinapril 67-76 angiotensin I converting enzyme Homo sapiens 98-101 2261144-10 1990 Second-generation ACE inhibitors (eg, enalapril and quinapril) are more potent sulfhydryl-free esters with a greater affinity for the converting enzyme. Quinapril 52-61 angiotensin I converting enzyme Homo sapiens 18-21 2261146-1 1990 Quinapril hydrochloride is a nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor that has been extensively tested and found effective when administered once-a-day to hypertensive patients of both sexes and all degrees of hypertension and cardiac compromise, including those with left ventricular hypertrophy, with and without congestive heart failure. Quinapril 0-23 angiotensin I converting enzyme Homo sapiens 43-72 2261146-1 1990 Quinapril hydrochloride is a nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor that has been extensively tested and found effective when administered once-a-day to hypertensive patients of both sexes and all degrees of hypertension and cardiac compromise, including those with left ventricular hypertrophy, with and without congestive heart failure. Quinapril 0-23 angiotensin I converting enzyme Homo sapiens 74-77 2261147-5 1990 Quinapril is a recently introduced, nonsulfhydryl ACE inhibitor, whose intermediate half-life makes it well-suited for the treatment of patients with CHF. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 50-53 2261147-6 1990 The acute and chronic hemodynamic effects of quinapril are similar to those of other ACE inhibitors. Quinapril 45-54 angiotensin I converting enzyme Homo sapiens 85-88 2074938-2 1990 The treatment with the particularly active ACE inhibitor quinapril failed but it suggested a procedure for a fast differential diagnosis of disease. Quinapril 57-66 angiotensin I converting enzyme Homo sapiens 43-46 2196144-0 1990 Hemodynamic effects of quinapril, a novel angiotensin-converting enzyme inhibitor. Quinapril 23-32 angiotensin I converting enzyme Homo sapiens 42-71 2196144-1 1990 The hemodynamic effects of quinapril, a novel nonsulfhydryl-containing angiotensin-converting enzyme (ACE) inhibitor, were assessed in 10 patients with mild-to-moderate essential hypertension. Quinapril 27-36 angiotensin I converting enzyme Homo sapiens 71-100 2196144-1 1990 The hemodynamic effects of quinapril, a novel nonsulfhydryl-containing angiotensin-converting enzyme (ACE) inhibitor, were assessed in 10 patients with mild-to-moderate essential hypertension. Quinapril 27-36 angiotensin I converting enzyme Homo sapiens 102-105 2189619-9 1990 The new ACE inhibitor quinapril has been shown to improve hemodynamic status both acutely and chronically and to produce dose-related improvements in exercise tolerance. Quinapril 22-31 angiotensin I converting enzyme Homo sapiens 8-11 2197098-8 1990 Inhibition of the renin-angiotensin system by quinapril was shown by a marked decrease in serum ACE activity and a several-fold increase in plasma renin activity (PRA). Quinapril 46-55 angiotensin I converting enzyme Homo sapiens 96-99 2197098-11 1990 The results indicate that, unlike the atenolol-induced beta-adrenoceptor blockade, ACE inhibition by a single dose of quinapril had no clear effect on autonomic nervous function or exercise capacity. Quinapril 118-127 angiotensin I converting enzyme Homo sapiens 83-86 1691402-0 1990 Overview of quinapril, a new ACE inhibitor. Quinapril 12-21 angiotensin I converting enzyme Homo sapiens 29-32 1691402-15 1990 Quinapril"s efficacy is comparable to that of other angiotensin-converting enzyme (ACE) inhibitors, and it has a lower incidence of adverse events or withdrawals due to adverse events than has been associated with captopril or enalapril. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 52-81 1691402-15 1990 Quinapril"s efficacy is comparable to that of other angiotensin-converting enzyme (ACE) inhibitors, and it has a lower incidence of adverse events or withdrawals due to adverse events than has been associated with captopril or enalapril. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 83-86 1691406-1 1990 In a double-blind, placebo-controlled, randomized, multicenter study, 225 patients with mild to moderate congestive heart failure (CHF) due to arterial hypertension and ischemic heart disease received quinapril, a new non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor, in addition to maintenance therapy with digitalis and/or diuretics. Quinapril 201-210 angiotensin I converting enzyme Homo sapiens 233-262 1691406-1 1990 In a double-blind, placebo-controlled, randomized, multicenter study, 225 patients with mild to moderate congestive heart failure (CHF) due to arterial hypertension and ischemic heart disease received quinapril, a new non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor, in addition to maintenance therapy with digitalis and/or diuretics. Quinapril 201-210 angiotensin I converting enzyme Homo sapiens 264-267 1691407-1 1990 Quinapril, a new angiotensin-converting enzyme (ACE) inhibitor with an intermediate duration of action, has been extensively studied in patients with hypertension and congestive heart failure (CHF) during a worldwide clinical development program. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 17-46 1691407-1 1990 Quinapril, a new angiotensin-converting enzyme (ACE) inhibitor with an intermediate duration of action, has been extensively studied in patients with hypertension and congestive heart failure (CHF) during a worldwide clinical development program. Quinapril 0-9 angiotensin I converting enzyme Homo sapiens 48-51 1691408-3 1990 Double-blind, long-term, open-label studies have been conducted of quinapril, a new angiotensin-converting enzyme (ACE) inhibitor, in 451 older patients compared with 1,887 younger patients. Quinapril 67-76 angiotensin I converting enzyme Homo sapiens 84-113 1691408-3 1990 Double-blind, long-term, open-label studies have been conducted of quinapril, a new angiotensin-converting enzyme (ACE) inhibitor, in 451 older patients compared with 1,887 younger patients. Quinapril 67-76 angiotensin I converting enzyme Homo sapiens 115-118 1691408-6 1990 However, because many older patients have impaired renal function, which can prolong the half-life of renally excreted ACE inhibitors such as quinaprilat (the active metabolite of quinapril), they should be started on lower doses of quinapril (5 mg) than are used in younger patients. Quinapril 142-151 angiotensin I converting enzyme Homo sapiens 119-122 1691408-6 1990 However, because many older patients have impaired renal function, which can prolong the half-life of renally excreted ACE inhibitors such as quinaprilat (the active metabolite of quinapril), they should be started on lower doses of quinapril (5 mg) than are used in younger patients. Quinapril 180-189 angiotensin I converting enzyme Homo sapiens 119-122 2553900-1 1989 The results of more than 1600 patient years of experience with the new angiotensin converting enzyme (ACE) inhibitor, quinapril, suggest that it is safe for the treatment of hypertension and congestive heart failure. Quinapril 118-127 angiotensin I converting enzyme Homo sapiens 102-105 2681603-4 1989 The angiotensin converting enzyme (ACE) inhibitors enalapril, ramipril, cilazapril and quinapril are prodrugs that are rapidly converted to active metabolites which are excreted unchanged through the kidneys. Quinapril 87-96 angiotensin I converting enzyme Homo sapiens 4-33 2681603-4 1989 The angiotensin converting enzyme (ACE) inhibitors enalapril, ramipril, cilazapril and quinapril are prodrugs that are rapidly converted to active metabolites which are excreted unchanged through the kidneys. Quinapril 87-96 angiotensin I converting enzyme Homo sapiens 35-38 2670220-2 1989 In patients with chronic heart failure, angiotensin-converting enzyme (ACE) inhibitors, such as captopril, enalapril, and quinapril, have been shown to improve hemodynamics, reduce symptoms of fatigue and dyspnea, increase exercise capacity, correct hyponatremia, reduce diuretic requirements and ventricular arrhythmias, and conserve potassium and magnesium. Quinapril 122-131 angiotensin I converting enzyme Homo sapiens 40-69 2670220-2 1989 In patients with chronic heart failure, angiotensin-converting enzyme (ACE) inhibitors, such as captopril, enalapril, and quinapril, have been shown to improve hemodynamics, reduce symptoms of fatigue and dyspnea, increase exercise capacity, correct hyponatremia, reduce diuretic requirements and ventricular arrhythmias, and conserve potassium and magnesium. Quinapril 122-131 angiotensin I converting enzyme Homo sapiens 71-74 2539762-2 1989 In studies of healthy volunteers, single quinapril doses of 0.625 mg to 80 mg inhibited plasma ACE activity for up to forty-eight hours. Quinapril 41-50 angiotensin I converting enzyme Homo sapiens 95-98 2459540-1 1988 Fourteen patients with mild to moderate essential hypertension were randomized, after a baseline placebo period of 4 weeks, to receive the angiotensin converting enzyme (ACE) inhibitor quinapril or a placebo. Quinapril 185-194 angiotensin I converting enzyme Homo sapiens 139-168 2459540-1 1988 Fourteen patients with mild to moderate essential hypertension were randomized, after a baseline placebo period of 4 weeks, to receive the angiotensin converting enzyme (ACE) inhibitor quinapril or a placebo. Quinapril 185-194 angiotensin I converting enzyme Homo sapiens 170-173 3020249-0 1986 Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. Quinapril 59-68 angiotensin I converting enzyme Homo sapiens 19-48 3020249-2 1986 The synthesis and angiotensin converting enzyme (ACE) inhibiting activities of quinapril (CI-906, 22), its active diacid (CI-928, 33), and its dimethoxy analogue (CI-925, 25) are reported. Quinapril 79-88 angiotensin I converting enzyme Homo sapiens 4-47 3020249-2 1986 The synthesis and angiotensin converting enzyme (ACE) inhibiting activities of quinapril (CI-906, 22), its active diacid (CI-928, 33), and its dimethoxy analogue (CI-925, 25) are reported. Quinapril 79-88 angiotensin I converting enzyme Homo sapiens 49-52 32416091-4 2020 The expressions of angiotensin-converting enzyme (ACE) and aminopeptidase N (AP-N) in HK2 cells were inhibited by quinapril and siRNA, respectively. Quinapril 114-123 angiotensin I converting enzyme Homo sapiens 19-48 32416091-4 2020 The expressions of angiotensin-converting enzyme (ACE) and aminopeptidase N (AP-N) in HK2 cells were inhibited by quinapril and siRNA, respectively. Quinapril 114-123 angiotensin I converting enzyme Homo sapiens 50-53 6090509-0 1984 Pilot study of the effects of the angiotensin-converting enzyme inhibitor CI-906 on patients with essential hypertension. Quinapril 74-80 angiotensin I converting enzyme Homo sapiens 34-63